Sequencing library prep that keeps native DNA ends intact
Raised to date
$2.3M
of $3.2M offered across 1 Form D filing
Canal Biosciences develops DNA library preparation technology for next-generation sequencing. Its proprietary TrueLink platform uses its own enzymes and adaptors in a simultaneous dual-ligation workflow that attaches sequencing adaptors directly to native DNA ends, skipping end repair. The company also offers DISTAL-seq and DISTAL-methyl-seq products aimed at liquid biopsy and methylation sequencing. Products are sold for research use only.
Ligates adaptors to native DNA ends without end repair or A-tailing, preserving true mutations, terminal structure, single-stranded molecules and methylation signals at fragment ends.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 13, 2026 | Equity | $2.3M/ $3.2M | Form D |
Sequencing library preparation reagent kit
NGS library prep platform using proprietary enzymes and adaptors in a dual-ligation workflow that attaches adaptors directly to native DNA ends.
Built for
Genomics researchers running next-generation sequencing, including liquid biopsy and methylation studies
